| 영문 | receptor | 한글 | 수용체 |
|---|---|---|---|
| 설명 | 세포질내 또는 세포표면에 존재하는 분자구조로서 특이물질과 선택적으로 결합하며 결합에 의해 특이한 생리적 작용을 나타낸다. 펩티드호르몬, 신경전달물질, 항원, 보체, 면역글로불린에 대한 세포표면 수용체와 스테로이드에 대한 세포질내 수용체가 있다. |
||
| 영문 | acetylcholine | 한글 | 아세틸콜린 |
|---|---|---|---|
| 설명 | 신경전달물질의 한 가지. 근육을 지배하는 신경의 말단에서 분비되어 근육의 수축을 유도하기도 하며, 부교감신경의 말단에서 분비되어 부교감신경의 전달을 담당하기도 하고, 뇌의 신경세포에서도 분비되어 여러 가지 작용을 한다. |
||
| 영문 | enzyme-linked immunoabsorbent assay | 한글 | 효소면역측정법 |
|---|---|---|---|
| 설명 | 효소결합면역흡착제 검정법으로 번역되고 있다. 이 법은 항원(또는 항체)에 알칼리 포스파타아제 또는 페르옥시디아제 등의 산소를 결합시켜 두고 그 산소활성을 지표로 삼아 항원항체반응의 정도를 안 다음 여기에서 항원(또는 항체)의 양을 구하는 것이다. 이 법의 이점으로서 고감도, 조작의 간단함 및 방사선면역측정법처럼 방사성물질을 사용하지 않아도 된다는 점을 들 수 있다. 호르몬이나 면역글로불린의 정량법으로서 응용 되고 있으며 측정용 키트도 시판되고 이있다. |
||
| 영문 | antiglobulin antibody | 한글 | 항글로불린항체 |
|---|---|---|---|
| 설명 | 항체에 대한 항체, 즉 특정 항체와 결합할 수 있는 항체. 대개 인간의 항체를 쥐에 주사하여 쥐로 하여금 인간 항체에 대한 항체를 만들게 한다(쥐에 있어서는 인간의 항체도 외부에서 들어온 물질이므로). 이것은 여러 가지 실험에서 인간의 특정항체를 검출하는데 이용한다. |
||
| 영문 | antibody | 한글 | 항체 |
|---|---|---|---|
| 설명 | 사람의 몸에서 면역에 관계하는 물질. 외부에서 들어온 물질과 꼭 맞게 결합을 하여서 그 물질의 생물학적 활동을 억제하거나 파괴하거나 사람의 다른 면역세포로 하여금 공격하기 용이하게 해주는 기능을 가지고 있다. 항체는 면역글로부린이라는 것으로 이루어져 있고 그 형태에 따라 IgA, IgE, IgG, IgD등으로 나눈다. |
||
| IFA | idiopathic fibrosing alveolitis; immunofluorescence assay; immunofluorescent antibody; incomplete Fr... |
|---|---|
| ERA | electrical response activity; electroencephalic response audiometry; Electroshock Research Associati... |
| AMA | against medical advice; alkaline membrane assay; American Management Association; American Medical A... |
| AChRAb | acetylcholine receptor antibody |
| ACA | abnormal coronary artery; acrodermatitis chronica atrophicans; acute cerebellar ataxia; adenocarcino... |
| AChR-AB | Acetylcholine Receptor Antibody |
|---|---|
| AChR | Acetylcholine Receptor |
| AcChR | Acetylcholine receptor |
| AcChoR | Acetylcholine receptor |
| AChR | Anti-acetylcholine receptor |
| acetylcholine receptor antibodies | <neurology, investigation> A test used to measure the amount of antibodies to acetylcholine receptors on nerve endings. This is a diagnostic test for myasthenia gravis. A normal value is no antibodies in the bloodstream. Acetylcholine receptor (AChR) binding autoantibodies (i.e. Antibodies reactive with several epitopes other than the binding site for acetylcholine or alpha-bungarotoxin) are present in approximately 88% of patients with generalised myasthenia gravis, 70% of ocular myasthenia and in approximately 80% of myasthenia gravis in remission. Although serum concentrations of AChR binding autoantibodies do not in general correlate well with severity of weakness, there is typical decrease in concentration as weakness improves with immunosuppressive therapy. AChR blocking autoantibodies (i.e., antibodies reactive with the AChR binding site) are present in about 50% of patients with myasthenia gravis, 30% with ocular myasthenia gravis and 20% of myasthenia gravis in remission, AChR blocking autoantibodies are the only AChR autoantibodies present in about 1% of myasthenia gravis. AChR modulating autoantibodies (i.e., autoantibodies which cross-link AChRs and cause their removal from muscle membrane surfaces) are present in more than 90% of myasthenia gravis and occasionally are the only AchR autoantibodies detectable in mild, recent onset or ocular-restricted myasthenia gravis. Results for AChR modulating autoantibodies can be transiently false-positive due to curare-like drugs used during general anesthesia. AChR autoantibodies of one or more types are found in at least 80% of ocular myasthenia gravis. Although generally absent in neurological conditions other than myasthenia gravis(and consequently unlikely to cause confusion in neurodiagnosis), false-positive results for AChR autoantibodies occasionally occur in primary biliary cirrhosis, tardive dyskinesia, autoimmune thyroiditis, the elderly, amyotrophic lateral sclerosis patients treated with cobra venom and patients with thymoma in the absence of myasthenia gravis. Approximately 1% of patients with rheumatoid arthritis treated with D-penicillamine develop AChR autoantibodies and myasthenia gravis, both of which disappear when the drug is discontinued. Babies born to ~10% of myasthenia gravis mothers have a transient neonatal form of myasthenia gravis that responds well to anticholinesterase therapy and usually remits within 1 month as maternal IgG disappears. (29 Dec 1997) |
|---|---|
| muscarinic acetylcholine receptor | Distinct from the nicotinic ACh receptor in having no intrinsic ion channel, the receptor is formed from one protein chain with 7 transmembrane regions. The receptors produce their effect via activation of GTP-binding proteins. (18 Nov 1997) |
| nicotinic acetylcholine receptor | Integral membrane protein of the postsynaptic membrane to which acetylcholine binds. The receptor contains an integral ion channel, as a result of binding of acetylcholine, ion channels in the subsynaptic membrane are opened. at the neuromuscular junction, the nicotinic acetylcholine receptor initiates muscle contraction. Currently the best characterised ion channel protein: made of a hetero pentamer of related subunits, although a homo pentamer is functional in insects. Structural studies show that the acetylcholine binding site and the ionic channel are part of the same macromolecular unit. The nAChR mediates rapid transduction events (1ms) whereas receptors activating G-protein coupled channels operate on slower time scales (millisecond to second range). (18 Nov 1997) |
| progesterone receptor assay | The progesterone receptor test (PgR assay) checks the tumour for its hormone status. (16 Dec 1997) |
| hormone receptor assay | A diagnostic test to determine whether a breast cancer's growth is influenced by hormones or if it can be treated with hormones. (09 Oct 1997) |
| double antibody sandwich assay | For antigen; an application of the ELISA method in which material being tested for antigen is added to wells coated with known antibody; the presence of antigen fixed to the antibody coat can be determined either directly, by adding human antibody linked to the enzyme of the indicator system, or indirectly, by first adding unlabelled known antibody, the attachment of which to the antigen can be demonstrated by addition of immunoglobulin-specific antibody linked to the enzyme. (05 Mar 2000) |
| acetylcholine | <chemical, neurology, physiology> A chemical found in vertebrate neurons that carries information across the synaptic cleft, the space between two nerve cells. (06 May 1997) |
| acetylcholine chloride | A miotic, administered as an ophthalmic solution for parasympathomimetic effect; used in cataract surgery. (05 Mar 2000) |
| thyroid receptor antibody | A test that measures the amount of an antibody (thyroid stimulating antibody) which is directed against a receptor for TSH on the thyroid gland. This antibody acts like TSH and stimulates the thyroid to produce excessive amounts of thyroid hormone. The presence of this antibody generally indicates Grave's disease (hyperthyroidism). (27 Sep 1997) |
| acetyl reduction assay | <investigation> A technique for measuring the nitrogen fixation activity in photosynthetic organisms. It uses a flame ionisation detector and a gas chromatography apparatus to determine the reduction of acetylene to ethylene by the enzyme nitrogenase. (06 May 1997) |
| Ames assay | <procedure> One of a number of procedures used to test substances for likely ability to cause cancer that combines the use of animal tissue to generate active metabolites of the substance with a test for mutagenicity in bacteria. (18 Nov 1997) |
| antibiotic assay | <investigation> A test to determine how sensitive a bacterial or fungal strain is to arange of antibiotics bymeasuring the microbes' ability to grow in astandard dilution of each chemical. (09 Oct 1997) |
| assay | <procedure> The determination of the amount of a particular constituent of a mixture or of the biological or pharmacological potency of a drug. (10 May 1997) |
| bandshift assay | <investigation> An assay for proteins, such as transcription factors, that bind specific DNA sequences. A labelled oligonucleotide corresponding to the recognition sequence is incubated with an appropriate nuclear protein extract and run on a nondenaturing acrylamide gel. Oligonucleotides that have been bound by proteins are retarded relative to those that are unbound. (18 Nov 1997) |
| biological assay | <technique> Once a pharmaceutical protein is isolated from the cells in which it was grown, researchers perform tests to measure the protein's biological activity. It must maintain a certain minimal level of biological activity to be used for animal or clinical testing or, later, for market. Researchers also test to confirm that the isolated protein is identical to the desired protein. (21 Mar 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|